Equity Overview
Price & Market Data
Price: $83.98
Daily Change: +$3.13 / 3.73%
Daily Range: $76.50 - $84.21
Market Cap: $233,950,400
Daily Volume: 9,647
Performance Metrics
1 Week: 10.33%
1 Month: 33.28%
3 Months: 137.2%
6 Months: 356.4%
1 Year: 1,300%
YTD: 99.29%
Company Details
Employees: 34
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.